Trials / Conditions / Peripheral Neuropathic Pain

Peripheral Neuropathic Pain

24 registered clinical trials studyying Peripheral Neuropathic Pain — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Evaluating Laser Photobiomodulation for the Treatment of Neuropathic Pain in Chemotherapy-induced Peripheral N NCT06834685	Institut du Cancer de Montpellier - Val d'Aurelle	N/A
Active Not Recruiting	Wearable Focused Ultrasound Stimulation for Peripheral Nerve Pain Management NCT07160049	University of Texas at Austin	N/A
Recruiting	Protocol Assessment of Motor Cortex rTMS for Treating Neuropathic Pain NCT06964243	Institut pour la Pratique et l'Innovation en PSYchologie appliquée (Institut Pi-Psy)	N/A
Not Yet Recruiting	Vitamin D Supplementation in Breast Cancer Patients NCT06596122	Abdelrahman Mahmoud	Phase 2
Recruiting	Response Profiles to High-concentration Capsaicin Desensitization in Patients with Peripheral Neuropathic Pain NCT05817591	Centre Hospitalier Annecy Genevois	—
Recruiting	Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain NCT05351801	VA Office of Research and Development	Phase 2
Recruiting	Clinical Trial of the Safety and Efficacy of Peripheral Nerve Stimulation in the Treatment of Peripheral Neuro NCT06290661	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	N/A
Completed	ACD440 Gel in Peripheral Neuropathic Pain NCT05416931	AlzeCure Pharma	Phase 2
Completed	To Evaluate the Long-term Safety and Efficacy of HSK16149 in Chinese Patients With Peripheral Neuralgia NCT05890053	Haisco Pharmaceutical Group Co., Ltd.	Phase 3
Completed	A Study to Learn How Safe BAY2395840 is and How Well it Works in Participants Who Have Diabetic Nerve Pain NCT05219812	Bayer	Phase 2
Completed	Increasing Sensori-Motor Rhythm Activity by EEG-Neurofeedback to Reduce the Impact of Pain on Daily Functionin NCT06234917	Institut pour la Pratique et l'Innovation en PSYchologie appliquée (Institut Pi-Psy)	N/A
Unknown	Evaluation of the Efficacy and Tolerance of Low Doses of Ethosuximide in the Treatment of Peripheral Neuropath NCT04431778	University Hospital, Clermont-Ferrand	Phase 2
Completed	A Phase 1b Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419 NCT04494815	Shanghai SIMR Biotechnology Co., Ltd.	Phase 1 / Phase 2
Unknown	Post-marketing Surveillance (PMS) to Observe the Safety and Effectiveness of Lyrica CR Extended Release Tablet NCT04171453	Viatris Korea	—
Completed	Burst Spinal Cord Stimulation for Neuropathic Pain. NCT03733886	Oslo University Hospital	N/A
Completed	Clinical Trial to Assess the Effect of Food on the Pharmacokinetics of YHD1119 in Healthy Volunteers NCT03191136	Yuhan Corporation	Phase 1
Completed	Clinical Trial of YHD1119 in Patients With Peripheral Neuropathic Pain NCT02985216	Yuhan Corporation	Phase 3
Completed	Randomized Controlled Trial of Efficacy and Safety of Local Anesthetics and Steroids for Chronic Peripheral Po NCT03009500	University Health Network, Toronto	Phase 3
Completed	BlueWind Reprieve System for the Treatment of PNP NCT02209896	BlueWind Medical	N/A
Completed	Assessment of the Effectiveness of Ethosuximide in the Treatment of Peripheral Neuropathic Pain. NCT02100046	University Hospital, Clermont-Ferrand	Phase 2
Completed	Observation of the Use of QUTENZA™ in Standard Clinical Practice NCT01737294	Astellas Pharma Europe Ltd.	—
Completed	NEP-TUNE: Neuropathic Pain - Treatment With Pregabalin Under Real-life Conditions in Denmark NCT01524796	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	—
Terminated	Molecular-Genetic Mechanisms Associated With Chemotherapy-Induced Nerve Damage NCT01293851	National Institute of Nursing Research (NINR)	—
Completed	Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal an NCT01240148	AstraZeneca	Phase 1